Amphastar Pharmaceuticals Inc vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.9 (market cap $868.62M), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $45.72. The key difference: Vanguard Global ex-US Real Estate Index Fd ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | VNQI | |
|---|---|---|
Market Cap | $868.62M | — |
Sector | Health | — |
52-Week High | $30.81 | $50.76 |
52-Week Low | $16.87 | $43.26 |
Enterprise Value | $1.27B | — |
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $19.87, down 2.19% today, with a bullish technical signal from moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.91, beating expectations, but missed in Q4 2025 and Q1 2026. Revenue for 2025 was $719.89M with a net income margin of 10.76%, while valuation ratios like P/E of 12.08 and EV/EBITDA of 6.57 suggest reasonable pricing. Recent news highlights growth from new product launches and ongoing FDA compliance efforts.
The outlook is mixed with growth opportunities from proprietary drugs and biosimilars, but risks include regulatory scrutiny and earnings volatility. Analyst sentiment is cautious with 25% buy ratings, reflecting concerns over execution and market pressures. Investors should weigh solid cash flow generation against competitive and regulatory headwinds for balanced exposure.
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $45.82, up 0.57% with a bullish technical signal from moving averages. The ETF provides diversified international real estate exposure across 30+ countries outside the US, featuring a higher dividend yield than domestic alternatives. Recent news highlights comparisons with US-focused REIT ETFs, emphasizing VNQI's global diversification benefits and competitive expense ratio.
The outlook remains positive given international real estate diversification and income appeal, though performance has lagged US counterparts. Key risks include currency fluctuations, geopolitical factors affecting foreign markets, and interest rate sensitivity. Institutional activity shows mixed signals with recent significant position reductions by some funds.
Trailing returns across standard periods
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →